Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31779| Title: | Plasma p-tau181/Aβ1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ1-42 and future cognitive decline. | Austin Authors: | Fowler, Christopher J;Stoops, Erik;Rainey-Smith, Stephanie R;Vanmechelen, Eugeen;Vanbrabant, Jeroen;Dewit, Nele;Mauroo, Kimberley;Maruff, Paul;Rowe, Christopher C ;Fripp, Jurgen;Li, Qiao-Xin;Bourgeat, Pierrick;Collins, Steven J;Martins, Ralph N;Masters, Colin L ;Doecke, James D | Affiliation: | The Florey Institute of Neuroscience and Mental Health ADx NeuroSciences Ghent Belgium. School of Medical and Health Sciences Centre of Excellence for Alzheimer's Disease Research & Care Edith Cowan University Joondalup Western Australia Australia. Cogstate Ltd Melbourne Victoria Australia. Australian E-Health Research Centre CSIRO Herston Queensland Australia. Department of Medicine (RMH) The University of Melbourne Melbourne Victoria Australia. |
Issue Date: | 2022 | Date: | 2022 | Publication information: | Alzheimer's and Dementia 2022 | Abstract: | In Alzheimer's disease (AD), plasma amyloid beta (Aβ)1-42 and phosphorylated tau (p-tau) predict high amyloid status from Aβ positron emission tomography (PET); however, the extent to which combination of these plasma assays can predict remains unknown. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31779 | DOI: | 10.1002/dad2.12375 | ORCID: | 0000-0003-2863-0293 | Journal: | Alzheimer's and Dementia | Start page: | e12375 | PubMed URL: | 36447478 | Type: | Journal Article | Subjects: | Alzheimer's disease amyloid beta amyloid imaging blood biomarkers blood diagnostic for Alzheimer's disease cerebrospinal fluid phosphorylated tau plasma amyloid beta plasma phosphorylated tau181 positron emission tomography |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.